ESC Premium Access

Is there a difference in treatment persistence across oral anticoagulants? Results of a UK cohort study evaluating oral anticoagulation therapy in an atrial fibrillation population

Congress Presentation

About the speaker

Ms Gillian Stynes

Uxbridge (United Kingdom of Great Britain & Northern Ireland)
0 follower

20 more presentations in this session

Prothrombin activation fragment (F1+2) as an index of anticoagulant therapy with factor Xa inhibitor in atrial fibrillation

Speaker: Doctor E. Ueno (Kahoku, JP)


Is major bleeding risk for oral anticoagulants similar between non-valvular atrial fibrillation patients newly initiated on warfarin and propensity-score matched NOAC initiators? A real world study

Speaker: Professor G. Lip (Liverpool, GB)


Differences in the characteristics of patients with non-valvular atrial fibrillation who are newly prescribed apixaban, rivaroxaban, dabigatran and VKA in general practice in the UK

Speaker: Ms G. Stynes (Uxbridge, GB)


The HAS-BLED score for prediction of stroke and systemic embolism: insights from the PREvention oF thromboembolic events, European Registry in Atrial Fibrillation (PREFER in AF)

Speaker: Doctor M. Rohla (Bern, CH)


Anticoagulation management in patients with atrial fibrillation undergoing elective electrical cardioversion

Speaker: Doctor O. Erkuner (Maastricht, NL)


Access the full session

Poster session 3 - Anticoagulation in atrial fibrillation

Speakers: Ms G. Stynes, Doctor E. Ueno, Professor G. Lip, Ms G. Stynes, Doctor M. Rohla...

About the event


ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb